A Phase 3 interventional study of Lapatinib (GW572016) oral tablets and Paclitaxel infusion in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Completed at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.
Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 9th largest by enrollment, is one of 13 that started in 2006, is one of 18 in phase 3, and was the 17th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 70 · Phase 3 18
First in 2003; this study’s year is marked. 13 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 444 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 35 across the 114 interventional studies. Of the 99 that completed or were terminated, 50 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 25th largest by enrollment of the 155 interventional ones that give a count, is one of 16 that started in 2006, is one of 45 in phase 3, and was the 25th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 114 studies testing lapatinib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, placebo-controlled, multicenter, Phase III study to evaluate and compare the efficacy and safety of Lapatinib + Paclitaxel versus Placebo + Paclitaxel in men and women with ErbB2 amplified metastatic (Stage IV) breast cancer who had not received prior therapy for metastatic disease.
Subjects were randomized to receive either Lapatinib (1500 mg once daily) + Paclitaxel (80 mg/m2 IV weekly for 3 weeks every 4 weeks) or Placebo (once daily) + Paclitaxel (80 mg/m2 IV weekly for 3 weeks every 4 weeks).
Subjects who progressed while on study and were on the placebo+paclitaxel arm were permitted to enter an extension phase of open label monotherapy therapy with lapatinib or open label combination therapy with lapatinib+paclitaxel and followed for response, progression and survival.
Based on the positive results in the primary analysis, Protocol Amendment 02 (dated 09 May 2011) discontinued further entry into the lapatinib monotherapy extension phase, and ongoing subjects taking placebo were permitted to replace it with open label lapatinib therapy (with or without continued paclitaxel therapy).
Following the primary Overall Survival (OS) analysis and subsequent implementation of Protocol Amendment 03, subjects who were still receiving active treatment entered the Long-term follow-up (LTFU) phase of the study. Reporting requirements in the LTFU phase were limited to Adverse events of special interest (AESI), Serious adverse events (SAEs) and pregnancy, and the subjects continued to receive treatment until the occurrence of unacceptable toxicity or disease progression (as determined by the investigator) or permanent withdrawal from treatment for any reason. Subjects who were no longer receiving active treatment were withdrawn from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases) Rapidly progressing or life threatening disease, as determined by the investigator Patients who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of investigational treatment;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paclitaxel and Lapatinib (Blinded)
Drug: Lapatinib (GW572016) oral tablets · Drug: Paclitaxel infusion
Paclitaxel and Placebo (Blinded)
Drug: Paclitaxel infusion · Drug: Placebo
Open Label - Monotherapy (Lapatinib)
Drug: Lapatinib (GW572016) oral tablets
Open Label - Combination Therapy (Lapatinib and Paclitaxel)
Drug: Lapatinib (GW572016) oral tablets · Drug: Paclitaxel infusion
1500 mg oral daily continuously
Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
Paclitaxel Matching Placebo
Overall Survival (OS) at 53 Months
Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.
Time frame: From date of randomization until date of death from any cause, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Overall Survival (OS) at 190 Months
Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.
Time frame: From date of randomization until date of death from any cause, assessed up to 190 months (Final OS analysis cut-off date = 23-Nov-2021)
Progression-free Survival (PFS) by Investigator Assessment
Progression-free survival (PFS) during the randomized phase was defined as the interval of time (in months) between the date of randomization and the earlier of date of disease progression (radiological or clinical assessment of symptomatic progression), or date of death due to any cause.
Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)
Overall Response Rate (ORR) by Investigator Assessment
Overall response rate (ORR) during the randomized phase was evaluated per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and defined as the percentage of subjects achieving either a Complete Response (CR) or a Partial Response (PR). Participants with unknown or missing responses were treated as non-responders.
Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)
Clinical Benefit Rate (CBR)
Clinical benefit rate (CBR) was defined as the percentage of subjects with evidence of CR or PR or stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of \>=1 new lesions\], taking as reference the smallest sum LD since treatment start) of \>=24 weeks, based on confirmed responses from the investigator assessment of best overall response during the randomized phase.
Time frame: From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary analysis cut-off date = 18-Jun-2010)
Duration of Response (DOR)
For subjects who show CR or PR, duration of response (DOR) was defined to be the time from first documented evidence of PR or CR until the first documented sign of disease progression (radiological or clinical assessment of symptomatic progression) or death due to any cause, if sooner during the randomized phase.
Time frame: From date of confirmed CR or PR until date of progression or date of death from any cause, whichever comes first, assessed up to 190 months (Final analysis cut-off date = 23-Nov-2021)
Number of Participants With a CR or PR at Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72
The original outcome measure to be analyzed was Time to response (TTR) during the randomized phase defined as the time from randomization until first documented evidence of PR or CR (whichever status was recorded first); however, data were presented as the number of participants with a response at each nominal visit. Responses were based on the investigator's assessment, and only participants with a confirmed CR or PR were included in this analysis.
Time frame: Weeks 8, 12, 16, 24, 32, 40, 48, 56, 64, and 72
Number of Tumors Evaluable for PIK3CA Mutations
Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.
Time frame: Baseline
Number of Participants With Tumors Evaluable for PTEN
Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression.
Time frame: Baseline
Predictive Effect of PIK3CA Mutations Status on Overall Response Rate (ORR)
ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.
Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Predictive Effect of PTEN Low on Overall Response Rate (ORR)
ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.
Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Predictive Effect of PIK3CA Mutations Status on Clinical Benefit Rate (CBR)
CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.
Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Predictive Effect of PTEN Low on Clinical Benefit Rate (CBR)
CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.
Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
This study was conducted in 43 centers in eight participating countries: Brazil (7), China (20), Hong Kong (3), Pakistan (3), Peru (1), Russian Federation (6), Thailand (2) and Ukraine (1).
| Milestone | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Open Label - Monotherapy | Open Label - Combination Therapy |
|---|---|---|---|---|
| Started | 222 | 222 | 0 | 0 |
| Safety population | 222 | 221 | 0 | 0 |
| Completed | 133 | 149 | 0 | 0 |
| Not completed | 89 | 73 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 34 | 27 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 7 | 0 | 0 |
| Withdrew: Study closed/terminated | 1 | 1 | 0 | 0 |
| Withdrew: Disease progression | 36 | 27 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 |
| Withdrew: Other reasons as defined per protocol | 4 | 3 | 0 | 0 |
| Withdrew: Reason for withdrawal unspecified | 4 | 5 | 0 | 0 |
| Withdrew: Treatment ongoing | 1 | 0 | 0 | 0 |
| Milestone | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Open Label - Monotherapy | Open Label - Combination Therapy |
|---|---|---|---|---|
| Started | 0 | 0 | 149 | 4 |
| Completed | 0 | 0 | 104 | 0 |
| Not completed | 0 | 0 | 45 | 4 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 16 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 2 |
| Withdrew: Disease progression | 0 | 0 | 18 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Relocation of patient | 0 | 0 | 1 | 0 |
| Withdrew: Reason for withdrawal unspecified | 0 | 0 | 5 | 0 |
Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.
| months | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Overall Survival (OS) at 53 Months | 27.8 (23.2 to 32.2) | 20.5 (17.9 to 24.3) |
Overall Survival (OS) was defined as the interval of time (in months) between the date of randomization and the date of death due to any cause.
| months | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Overall Survival (OS) at 190 Months | 27.6 (23.7 to 31.5) | 20.3 (17.9 to 24.3) |
Progression-free survival (PFS) during the randomized phase was defined as the interval of time (in months) between the date of randomization and the earlier of date of disease progression (radiological or clinical assessment of symptomatic progression), or date of death due to any cause.
| months | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Progression-free Survival (PFS) by Investigator Assessment | 9.7 (9.2 to 11.1) | 6.5 (5.5 to 7.3) |
Overall response rate (ORR) during the randomized phase was evaluated per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and defined as the percentage of subjects achieving either a Complete Response (CR) or a Partial Response (PR). Participants with unknown or missing responses were treated as non-responders.
| Percentage of Participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Overall Response Rate (ORR) by Investigator Assessment | 69 (62.9 to 75.4) | 50 (42.8 to 56.3) |
Clinical benefit rate (CBR) was defined as the percentage of subjects with evidence of CR or PR or stable disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of \>=1 new lesions\], taking as reference the smallest sum LD since treatment start) of \>=24 weeks, based on confirmed responses from the investigator assessment of best overall response during the randomized phase.
| Percentage of Participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Clinical Benefit Rate (CBR) | 75 (68.5 to 80.3) | 56 (49.1 to 62.5) |
For subjects who show CR or PR, duration of response (DOR) was defined to be the time from first documented evidence of PR or CR until the first documented sign of disease progression (radiological or clinical assessment of symptomatic progression) or death due to any cause, if sooner during the randomized phase.
| months | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Duration of Response (DOR) | 9.3 (7.7 to 10.7) | 5.8 (5.6 to 7.4) |
The original outcome measure to be analyzed was Time to response (TTR) during the randomized phase defined as the time from randomization until first documented evidence of PR or CR (whichever status was recorded first); however, data were presented as the number of participants with a response at each nominal visit. Responses were based on the investigator's assessment, and only participants with a confirmed CR or PR were included in this analysis.
| Participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| Week 8 | 94 | 61 |
| Week 12 | 40 | 28 |
| Week 16 | 6 | 11 |
| Week 24 | 7 | 8 |
| Week 32 | 3 | 2 |
| Week 40 | 0 | 0 |
| Week 48 | 1 | 0 |
| Week 56 | 1 | 0 |
| Week 64 | 1 | 0 |
| Week 72 | 1 | 0 |
Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.
| Participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| PIK3CA mutation | 29 | 36 |
| PIK3CA wild-type | 58 | 48 |
| PIK3CA indeterminate | 17 | 22 |
Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression.
| Participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| PTEN IHC 0 | 28 | 21 |
| PTEN IHC 1+ | 76 | 80 |
| PTEN IHC 2+/3+ | 76 | 74 |
ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.
| percentage of participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| PIK3CA mutation | 62 | 50 |
| PIK3CA wild-type | 80 | 59 |
ORR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving either CR or PR. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.
| percentage of participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| PTEN low | 73 | 53 |
| Without PTEN low | 76 | 58 |
CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. A PIK3CA mutation test kit was used to assess mutation status on genomic deoxyribonucleic acid (DNA) isolated from tumor tissue.
| percentage of participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| PIK3CA mutation | 69 | 56 |
| PIK3CA wild-type | 84 | 65 |
CBR was evaluated per RECIST v1.1 and defined as the percentage of subjects achieving CR or PR or stable disease. Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) was studied to evaluate the predictive and prognostic value of PIK3CA mutations and/or PTEN low in HER2-positive patients receiving first-line treatment with paclitaxel alone or in combination with lapatinib. Immunohistochemistry (IHC) staining in an analytically validated assay was used in the assessment of PTEN protein expression on tumor tissue. Staining intensity was allocated a score of 0, 1+, 2+ or 3+. Tumors scored IHC 0 were considered as exhibiting an absence of PTEN expression whereas those scored ICH 1+, 2+ or 3+ were considered as exhibiting any PTEN expression, being 3+ the highest expression. Tumors scored IHC 0/1+ were considered PTEN low.
| percentage of participants | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel |
|---|---|---|
| PTEN low | 82 | 59 |
| Without PTEN low | 80 | 61 |
Collected over From study treatment start date till 30 days safety follow-up, assessed up to 190 months (Final OS analysis cut-off date = 23-Nov-2021). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lapatinib 1500 mg + Paclitaxel | 10/222 (4.5%) | 67/222 (30.2%) | 219/222 (98.6%) |
| Placebo + Paclitaxel | 15/221 (6.8%) | 30/221 (13.6%) | 206/221 (93.2%) |
| Open Label - Monotherapy | 2/149 (1.3%) | 8/149 (5.4%) | 86/149 (57.7%) |
| Open Label - Combination Therapy | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Open Label - Monotherapy | Open Label - Combination Therapy |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 36/222 | 10/221 | 0/149 | 0/4 |
| Ejection fraction decreasedInvestigations | 13/222 | 3/221 | 0/149 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 10/222 | 0/221 | 1/149 | 0/4 |
| LeukopeniaBlood and lymphatic system disorders | 7/222 | 1/221 | 0/149 | 0/4 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/222 | 1/221 | 0/149 | 0/4 |
| GranulocytopeniaBlood and lymphatic system disorders | 4/222 | 0/221 | 0/149 | 0/4 |
| Left ventricular dysfunctionCardiac disorders | 3/222 | 0/221 | 0/149 | 0/4 |
| PyrexiaGeneral disorders | 3/222 | 0/221 | 1/149 | 0/4 |
| Femur fractureInjury, poisoning and procedural complications | 0/222 | 2/221 | 0/149 | 0/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/222 | 2/221 | 0/149 | 0/4 |
| Event | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Open Label - Monotherapy | Open Label - Combination Therapy |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 172/222 | 64/221 | 42/149 | 0/4 |
| NeutropeniaBlood and lymphatic system disorders | 168/222 | 103/221 | 5/149 | 0/4 |
| AlopeciaSkin and subcutaneous tissue disorders | 104/222 | 119/221 | 2/149 | 0/4 |
| LeukopeniaBlood and lymphatic system disorders | 113/222 | 74/221 | 6/149 | 0/4 |
| Dry skinSkin and subcutaneous tissue disorders | 16/222 | 3/221 | 8/149 | 2/4 |
| RashSkin and subcutaneous tissue disorders | 109/222 | 47/221 | 52/149 | 0/4 |
| Decreased appetiteMetabolism and nutrition disorders | 70/222 | 41/221 | 3/149 | 0/4 |
| NauseaGastrointestinal disorders | 66/222 | 44/221 | 4/149 | 0/4 |
| Mucosal erosionGeneral disorders | 0/222 | 0/221 | 0/149 | 1/4 |
| Blood bilirubin increasedInvestigations | 7/222 | 5/221 | 2/149 | 1/4 |
| Age, Continuous(Years) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| Mean | 49.1 ± 10.74 | 49.3 ± 9.75 | 49.2 ± 10.25 |
| Sex: Female, Male(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| Female | 222 | 217 | 439 |
| Male | 0 | 5 | 5 |
| Race/Ethnicity, Customized(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| White | 9 | 13 | 22 |
| Asian | 192 | 192 | 384 |
| Hispanic | 21 | 16 | 37 |
| Other | 0 | 1 | 1 |
| Number of participants with any visceral metastatic disease and with only non-visceral disease(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| Visceral | 187 | 186 | 373 |
| Non-visceral | 35 | 36 | 71 |
| Number of Participants with the Indicated Hormone Receptor Status(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| ER+ and/or PgR+ or Unknown | 111 | 113 | 224 |
| ER- and PgR- | 111 | 109 | 220 |
| Number of Participants with the Indicated Stage of Disease at Initial Diagnosis(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| Stage I to II | 107 | 119 | 226 |
| Stage III | 75 | 68 | 143 |
| Stage IV | 30 | 24 | 54 |
| Unknown | 10 | 11 | 21 |
| Number of Participants with the Indicated Eastern Cooperative Oncology Group Performance Status(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| 0, Fully Active | 103 | 113 | 216 |
| 1, Ambulatory, Restricted Strenuous Activity | 119 | 109 | 228 |
| Number of Participants with the Indicated Number of Metastatic Sites(Participants) | Lapatinib 1500 mg + Paclitaxel | Placebo + Paclitaxel | Total |
|---|---|---|---|
| Greater than or equal to 3 | 131 | 115 | 246 |
| Less than 3 | 91 | 107 | 198 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jan 2006 to primary completion in Jun 2010, 53 months.
Results were first posted in Jun 2011, 11 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 53 months is above that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lapatinib · Paclitaxel